Image Source: The Economic Times
Biocon Ltd has released its Q4 FY24 results, declaring total income at ₹44.54 billion and net profit at ₹3.45 billion. Revenue continued its steady upswing, but net profit fell as a result of increased operational expenditures and market pressures.
Major Points
Revenue Growth & Market Performance
Biocon's total income was at ₹44.54 billion, increasing YoY by 4%.
The biosimilars division of the company contributed notably, exceeding USD 1 billion annually in revenues.
Net Profit Slump & Inflationary Pressure
Net profit fell 57% YoY to ₹3.45 billion due to an increase in input costs and operating expenses.
EBITDA margins fell to 23.4% from 26.4%, an effect of cost pressure in the pharmaceutical industry.
Strategic Foray & Expansion Initiatives
Biocon is also increasing its portfolio of biosimilars with recent approvals granted for Liraglutide in the UK.
The firm intends to seize GLP-1 market opportunities, further ensuring global presence.
Dividend Declaration & Shareholder Returns
Biocon's board of directors has proposed a final dividend of ₹0.50 per equity share, pending shareholder approval.
Dividend will be dispatched on or before September 6, 2024.
Future Outlook & Growth Strategy
Biocon intends to lower acquisition debt, ensuring financial stability.
The firm remains confident of long-term growth, through strategic partnerships and market expansion.
This financial achievement reflects Biocon's strength, solidifying its position in the international biopharmaceutical sector.
Sources: Biocon Official Report, Mint, Business Standard
Advertisement
Advertisement